Medgenics is engaged in developing and commercializing Biopump, a novel technology for the sustained production and delivery of therapeutic proteins utilizing patients’ own skin biopsies. Biopump is designed to treat various chronic diseases including anemia, hepatitis and hemophilia. Based on this technology, the company is currently developing three long-acting protein therapy products: EPODURE, INFRADURE and HEMODURE. Medgenics additionally has a pipeline of other Biopump products in view. For more information, visit the company’s Web site at www.medgenics.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: